REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On May 10, 2018, Revance Therapeutics, Inc. (the “Company”) entered into a Fourth Amendment to Lease (the “Amendment”) with BMR-Pacific Research Center LP, a Delaware limited partnership (formerly known as BMR-Gateway Boulevard LLC) (the “Landlord”), which amended the Lease dated March 31, 2008 (as amended in the First Amendment to Lease dated April 7, 2008, the Second Amendment to Office Lease and Lease dated May 17, 2010 and the Third Amendment to Lease dated February 26, 2014, collectively the “Existing Lease”), to which the Company leases certain premises located at 7555 Gateway Boulevard, Newark, California (the “Existing Premises”). The Amendment expanded the Existing Premises to include certain space in the building located at 7999 Gateway Boulevard, Newark, California (the “Additional Premises”) and extended the term of the Existing Lease by twenty-four (24) months (the “Extension Term”). The annual base rent for the Existing Premises during the Extension Term of the lease term will range from $5,075,628 to $5,227,464. The monthly base rent for the Additional Premises will be $0 for the first two months and $58,714 per month for the next ten months, with annual increases of 3% of the then-current base rent.
The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 hereto.
|
Item 1.01 |
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
At the Company’s 2018 annual meeting of stockholders held on May10, 2018, the stockholders voted on the two proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2018 annual meeting, filed with the Securities and Exchange Commission on March20, 2018. The results of the matters voted upon at the meeting were:
|
a) |
Each of the Class I nominees of the Company’s Board of Directors were elected to hold office until the Company’s 2021 annual meeting of stockholders. The Class I nominees were: Angus C. Russell; 24,089,371 shares of Common Stock voted for, 3,547,209 withheld, and 6,806,581 broker non-votes; Phyllis Gardner, M.D.; 25,144,775 shares of Common Stock voted for, 2,491,805 withheld, and 6,806,581 broker non-votes;and Julian S. Gangolli; 25,144,653 shares of Common Stock voted for, 2,491,927 withheld, and 6,806,581 broker non-votes. The term of office of Class II director Mark J. Foley continues until the Company’s 2019 annual meeting of stockholders. The terms of office of Class III directors L. Daniel Browne, Robert Byrnes, and Philip J. Vickers, Ph.D. continue until the Company’s 2020 annual meeting of stockholders. |
|
b) |
The stockholders ratified the selection by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December31, 2018: 34,131,146 shares of Common Stock voted for, 210,091 against, 101,924 abstaining, and no broker non-votes. |
|
Item 1.01 |
FINANCIAL STATEMENTS AND EXHIBITS. |
(d) Exhibits.
Revance Therapeutics, Inc. ExhibitEX-10.1 2 rvncexhibit101.htm EXHIBIT 10.1 Exhibit Exhibit 10.1FOURTH AMENDMENT TO LEASETHIS FOURTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 10th day of May,…To view the full exhibit click here
About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.
